Hatlevoll R, Hagen S, Hansen H S, Hultborn R, Jakobsen A, Mäntylä M, Modig H, Munck-Wikland E, Nygaard K, Rosengren B
Norwegian Radium Hospital, Oslo.
Radiother Oncol. 1992 Jun;24(2):114-6. doi: 10.1016/0167-8140(92)90288-6.
Survival and swallowing function were studied in a randomized trial of 97 patients with inoperable, localized esophageal carcinoma. Radical radiotherapy was given to 51 patients, while 46 patients had two courses of bleomycin/cisplatin before radiotherapy. The survival was 29% after one year, and 6% after 3 years in the radiotherapy group. The survival in the combined treatment group was 18 and 0%, respectively; p = 0.1895. The number of patients who could swallow any food increased from 6% before treatment to 38% after 3 months in the radiotherapy group, and from 0% to 23% in the combined group. No benefit was found by combining bleomycin/cisplatin with radiotherapy.
在一项针对97例无法手术的局限性食管癌患者的随机试验中，对生存情况和吞咽功能进行了研究。51例患者接受了根治性放疗，而46例患者在放疗前接受了两个疗程的博来霉素/顺铂治疗。放疗组1年后生存率为29%，3年后为6%。联合治疗组的生存率分别为18%和0%；p = 0.1895。放疗组能够吞咽任何食物的患者数量从治疗前的6%增加到3个月后的38%，联合组则从0%增加到23%。未发现博来霉素/顺铂与放疗联合使用有任何益处。
